<DOC>
	<DOCNO>NCT00993499</DOCNO>
	<brief_summary>The primary objective trial identify Maximum Tolerated Dose BIBW 2992 therapy give continuously combination Sirolimus . The MTD base Dose Limiting Toxicity information collect first two cycle . Overall safety , pharmacokinetics anti-tumour efficacy evaluate secondary objective .</brief_summary>
	<brief_title>Trial Continuous Once Daily Oral Treatment Using BIBW 2992 ( Afatinib ) Plus Sirolimus ( Rapamune® ) Patients With Non-small Cell Lung Cancer Harbouring EGFR Mutation and/or Disease Progression Following Prior Erlotinib Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically cytologically confirm diagnosis Stage IIIB Stage IV NSCLC 2 . Patients fail conventional treatment ( least 1 prior treatment line ) , therapy proven efficacy exist 3 . Patients whose tumor : EGFR mutationpositive EGFR mutationnegative unknown provide disease progression achieve either response stable disease least 6 month previous treatment erlotinib ( Tarceva® ) gefitinib ( Iressa® ) 4 . Patients age 18 year old 5 . Life expectancy least three ( 3 ) month 6 . Eastern Cooperative Oncology Group ( ECOG , R010787 ) performance score 02 7 . Written inform consent consistent ICHGCP guideline Exclusion criterion : 1 . Prior major surgery , chemotherapy radiation therapy within 4 week start therapy . 2 . Prior treatment mTOR inhibitor within past 4 week start therapy concomitantly study 3 . Use erlotinib ( Tarceva® ) gefitinib ( Iressa® ) within 14 day runin treatment Sirolimus 4 . Active CNS metastasis ( define stable &lt; 4 week and/or symptomatic and/or require treatment anticonvulsant steroid ) 5 . Severe alteration serum fast cholesterol ( equal 350 mg/dL ) triglyceride ( equal 400 mg/dL ) . Patients may allow enrol trial initiation lipid lower agent . 6 . Requirement treatment prohibit concomitant medication : Concomitant CYP3A4 inhibitor within past 7 day start therapy concomitantly study . Concomitant CYP3A4 inducer within past 14 day start therapy concomitantly study . 7 . Any contraindication therapy Sirolimus . 8 . Known hypersensitivity BIBW 2992 , Sirolimus rapamycin analogue ( everolimus , temsirolimus , deforolimus , etc . ) excipients trial drug . 9 . Use investigational drug within 4 week start therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>